Herbert Irving Comprehensive Cancer Center

Ironing Out Cancer Columbia researchers have discovered the natural mechanism behind a type of cell death called ferroptosis - solving a longstanding puzzle in cell biology.

‼️After a decade+ of research, @columbiamed.bsky.social scientists led by Wei Gu have discovered the natural mechanism behind a novel form of cell death called ferroptosis. Read about this work in @cellpress.bsky.social www.cancer.columbia.edu/news/ironing...

New research led by Andrea Califano, Dr, unveils a framework to decode hundreds of thousands of previously “uninterpretable” cancer mutations— helping clinicians prioritize more effective treatments and avoid unnecessary ones. @biohub.org
🔗 www.cancer.columbia.edu/news/turning...

Wakenda Tyler, MD: Bringing Health Equity into Sarcoma Care In honor of Black History Month, we spoke with Dr. Tyler about why she thinks disparities research should be a priority in sarcoma care.

Sarcoma is rare, but inequities in life-saving care are widespread in underserved communities. Read how Wakenda Tyler, MD, is pushing the field to confront disparities, like higher amputation and mortality rates. #BlackHistoryMonth @columbiamed.bsky.social www.cancer.columbia.edu/news/wakenda...

GLP-1 Weight Loss Drugs and Cancer: Is There a Link? GLP-1 weight-loss medications have changed how doctors treat obesity- here’s what we know about their impact on cancer.

💭 Do GLP-1s raise, lower, or not affect cancer risk?
As GLP-1 drugs surge in popularity, so have questions about their safety, especially around cancer. Based on current evidence, the answer is reassuring and increasingly hopeful. ⤵️ www.cancer.columbia.edu/news/glp-1-w...

Testing Drug Responses, Not Just Genes: A New Functional Precision Medicine Trial Comes to Columbia We spoke with Rob Wechsler-Reya, PhD, about a novel functional precision medicine approach that he developed, which is being tested in a national clinical trial now opening at Columbia.

A national clinical trial open at
@columbiamed.bsky.social is testing a new precision medicine approach developed by Rob Wechsler-Reya, PhD- directly testing how each patient’s tumor cells respond to different drugs, rather than testing genetics alone. →
www.cancer.columbia.edu/news/q-testi...

2025 Annual Report The Herbert Irving Comprehensive Cancer Center earned renewed Comprehensive Cancer Center designation from the National Cancer Institute for 2025–2030, with $27 million in funding to strengthen cancer...

The 2025 issue of Pathways to a Cure is here!
See how HICCC is driving breakthroughs in cell therapy, AI precision prevention, and early-onset cancers—while expanding access to world-class care at Columbia.
Read now ⬇️
pubs.cancer.columbia.edu/reports/2025...

Engineering bispecific exosome activators of T cells to target immune checkpoint inhibitor-resistant metastatic melanoma - @columbiacancer.bsky.social go.nature.com/496Ins7

HICCC is presenting at #ASH2025! Follow along for highlights on research from Columbia at this year’s American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando.
↘️Be sure to tag us to be promoted!
View more: mailchi.mp/cumc/hiccc-w...

What to Know About Liquid Biopsies for Cancer Liquid biopsies have the potential to transform cancer care. We asked Dr. Chin Hur how these tests fit into the future of personalized cancer screening, now that one has FDA approval.

The first FDA-approved liquid biopsy test for cancer screening is here - and raising big questions about how it could transform cancer care. HICCC’s Dr. Chin Hur weighs in. More in this Q&A 👉 cancer.columbia.edu/news/what-kn...

The Spring/Summer issue of Accelerations is here!
We're spotlighting momentum— discover what's next in cancer research, breakthroughs in drug discovery, and progress in pancreatic cancer.
Read the issue below.
hiccc-accelerations.onpubli.com/Spring-Summe...

Getting through the blood-brain barrier remains a huge challenge in brain tumor treatment. Read how HICCC researchers Elisa Konofagou & Stergios Zacharoulis are using #soundwaves to open it just long enough to deliver therapy.
engineering.columbia.edu/about/news/t...

Uterine Cancer Rates Predicted to Rise, Especially Among Black Women A new study forecasts a substantial rise in uterine cancer cases and deaths over the next three decades, with a disproportionate impact on Black women.

Uterine cancer is one of the few cancers with rising incidence and mortality. A new @columbiamed.bsky.social study led by HICCC’s Jason D. Wright projects a sharp increase over the next 30 years—disproportionately impacting Black women. Read more: www.cuimc.columbia.edu/news/uterine...

Last week, we celebrated the official launch of the Center for Innovation in Imaging Biomarkers and Integrated Diagnostics (CIMBID) at Columbia. @columbiamed.bsky.social
Catch the highlights and recordings below.
@columbiaimaging.bsky.social
columbiaradiology.org/news/columbi...

2025 IICD Intensive Workshop first day in classroom

Today marks Day 1 of the second cohort of the 2025 IICD Intensive Workshop. We’re thrilled to welcome a new group of graduate students and postdocs for a week of immersive learning! #CancerResearch #STEMeducation @elhamazizi.bsky.social @columbiamed.bsky.social @columbiacancer.bsky.social

Tattoos and Skin Cancer: A Cause for Concern? Mariam El-Ashmawy, MD, PhD, shares what you need to know about tattoos and skin cancer—and how to protect your skin for the long run.

Tattoos last forever-but do they come with health risks that stick around just as long? 💭 HICCC's Dr. Mariam El-Ashmawy breaks down what early research shows —and what you can do to protect your skin with or without tattoos. www.cancer.columbia.edu/news/tattoos...

Brent Stockwell presenting to SRP

The SRP interns had a great seminar with Dr. @brentstockwell.bsky.social

Thank you, Dr. Stockwell, for sharing your career path and research with our summer interns! 🔬✨
#CancerResearch #STEMeducation #IICDSR #SummerInternship @columbiacancer.bsky.social

Highlights from HICCC's 3rd Annual Clinical Trials Day at
@columbiamed.bsky.social 🏥👏 Thank you to everyone who joined us last week to learn about the urgent need for broader participation in #ClinicalTrials

6/3, 10:45 AM EST/9:45 AM CDT , A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT04511013). Authors: Vadim Spektor. meetings.asco.org/2025-asco-an...

6/3, 10:45 AM EST/ 9:45 AM, Does the Road to Cure Myeloma End with Minimal Residual Disease?. Discussant: Suzanne Lentzsch, MD, PhD. meetings.asco.org/2025-asco-an...

View today's final HICCC #ASCO2025 daily roundup, below!

6/2, 8:00 AM CDT, Efficacy and safety of dordaviprone (ONC201) in prospective clinical trials of adult and pediatric recurrent H3 K27M-mutant diffuse glioma patients.
Author: Aya Haggiagi
meetings.asco.org/2025-asco-an...

6/2, 9:45 AM CDT, A first-in-human study of DYP688, an antibody drug conjugate delivering a direct Gq/11 inhibitor, in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas.
Author: Alexander Wei. meetings.asco.org/2025-asco-an...

6/2, 8:00 AM CDT, Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial.
Author: Rajshekhar Chakraborty. meetings.asco.org/2025-asco-an...

6/2, 8:00 AM CDT, Linvoseltamab (LINVO) + bortezomib (BTZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): First results from the LINKER-MM2 trial.
Author: Rajshekhar Chakraborty. meetings.asco.org/2025-asco-an...

6/2, 8:00 AM CDT, Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial.
Author: Rajshekhar Chakraborty. meetings.asco.org/2025-asco-an...

View today's HICCC #ASCO2025 daily roundup, below!

5/31, 1:15 PM CDT. Phase I/Ib study of INAVO alone and in combination with endocrine therapy ± palbociclib in patients (pts) with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer.
Author: Melissa Accordino
meetings.asco.org/2025-asco-an...

5/31, 3:00 PM CDT. Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma.
Author: Ran Reshef
meetings.asco.org/2025-asco-an...

5/31, 3:00 PM CDT. Use of lucicebtide (ST101) in glioblastoma patients by antagonism of C/EBPβ-dependent mesenchymal cell transition and immunosuppressive M2 macrophage polarization.
Presenter: Fabio Massaiti Iwamoto
meetings.asco.org/2025-asco-an...

5/31, 8:00 AM CDT, Association between allostatic load and breast radiomic features among diverse women undergoing screening mammography.
Presenter: Sara Wallam
meetings.asco.org/2025-asco-an...